Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes. What to add-Insulin glargine or pioglitazone?

Diabetes Research and Clinical Practice

Volumn 82, Issue 3, 2008, Pages 340-345

  Dorkhan, Mozhgan ^a   Frid, Anders ^a   Groop, Leif ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cell function; Adiponectin; Insulin sensitivity; Natriuretic peptides; Proinsulin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C PEPTIDE; CHOLESTEROL; GLIPIZIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PROINSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; BENZAMIDES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEART FUNCTION TESTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; MIDDLE AGED; PROINSULIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55549100567     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.009     Document Type: Article

References (21)

1. DeFronzo R.A., Bonadonna R.C., and Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15 3 (1992) 318-368
2. Singh S., Loke Y.K., and Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30 8 (2007) 2148-2153
3. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51 1 (2008) 8-11
4. Bradley C. A guide to psychological measurement in diabetes research and practice. In: Bradley C. (Ed). Handbook of Psychology and Diabetes (1994), Harwood Academic 111-152
5. Bradley C., and Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diab. Metab. Res. Rev. 18 Suppl. 3 (2002) S64-S69
6. Dorkhan M., Tripathy D., Malm G., Asgharian H., Tuomi T., and Groop L. Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test. J. Intern. Med. 264 1 (2008) 62-71
7. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371 9626 (2008) 1753-1760
8. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Meigs J.B., et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 30 2 (2007) 318-324
9. Dekker J.M., Funahashi T., Nijpels G., Pilz S., Stehouwer C.D., Snijder M.B., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J. Clin. Endocrinol. Metab. (2008)
10. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., Cacciatori V., et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J. Clin. Endocrinol. Metab. 68 2 (1989) 374-378
11. Kotronen A., Seppala-Lindroos A., Bergholm R., and Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 51 1 (2008) 130-138
12. Juurinen L., Kotronen A., Graner M., and Yki-Jarvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J. Clin. Endocrinol. Metab. 93 1 (2008) 118-124
13. Andrews W.J., Vasquez B., Nagulesparan M., Klimes I., Foley J., Unger R., et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33 7 (1984) 634-642
14. Natali A., and Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49 3 (2006) 434-441
15. Triplitt C., Glass L., Miyazaki Y., Wajcberg E., Gastaldelli A., De Filippis E., et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 29 11 (2006) 2371-2377
16. Aljabri K., Kozak S.E., and Thompson D.M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am. J. Med. 116 4 (2004) 230-235
17. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 3 (2006) 554-559
18. Basu R., Pajvani U.B., Rizza R.A., and Scherer P.E. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 56 8 (2007) 2174-2177
19. Yu C.M., Sanderson J.E., Shum I.O., Chan S., Yeung L.Y., Hung Y.T., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur. Heart J. 17 11 (1996) 1694-1702
20. Bursi F., Weston S.A., Redfield M.M., Jacobsen S.J., Pakhomov S., Nkomo V.T., et al. Systolic and diastolic heart failure in the community. JAMA 296 18 (2006) 2209-2216
21. Gaede P., Hildebrandt P., Hess G., Parving H.H., and Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48 1 (2005) 156-163